Lannuzel Annie, Höglinger G U, Verhaeghe S, Gire L, Belson S, Escobar-Khondiker M, Poullain P, Oertel W H, Hirsch E C, Dubois B, Ruberg M
Department of Neurology, Hospital of Pointe-à-Pitre, Guadeloupe, F.W.I.
Brain. 2007 Mar;130(Pt 3):816-27. doi: 10.1093/brain/awl347. Epub 2007 Feb 15.
In Guadeloupe, there is an abnormally high frequency of atypical parkinsonism. Only one-third of the patients that develop parkinsonian symptoms were reported to present the classical features of idiopathic Parkinson disease and one-third a syndrome resembling progressive supranuclear palsy (PSP). The others were unclassifiable, according to established criteria. We carried out a cross-sectional study of 160 parkinsonian patients to: (i) define more precisely the clinical phenotypes of the PSP-like syndrome and the parkinsonism that was considered unclassifiable in comparison with previously known disorders; (ii) define the neuropsychological and brain imaging features of these patients; (iii) evaluate to what extent a candidate aetiological factor, the mitochondrial complex I inhibitor annonacin contained in the fruit and leaves of the tropical plant Annona muricata (soursop) plays a role in the neurological syndrome. Neuropsychological tests and MRI were used to classify the patients into those with Parkinson's disease (31%), Guadeloupean PSP-like syndrome (32%), Guadeloupean parkinsonism-dementia complex (PDC, 31%) and other parkinsonism-related disorders (6%). Patients with a PSP-like syndrome developed levodopa-resistant parkinsonism, associated with early postural instability and supranuclear oculomotor dysfunction. They differed, however, from classical PSP patients by the frequency of tremor (>50%), dysautonomia (50%) and the occurrence of hallucinations (59%). PDC patients had levodopa-resistant parkinsonism associated with frontosubcortical dementia, 52% of these patients had hallucinations, but, importantly, none had oculomotor dysfunction. The pattern of neuropsychological deficits was similar in both subgroups. Cerebral atrophy was seen in the majority of the PSP-like and PDC patients, with enlargement of the third ventricle and marked T2-hypointensity in the basal ganglia, particularly the substantia nigra. Consumption of soursop was significantly greater in both PSP-like and PDC patients than in controls and Parkinson's disease patients. In conclusion, atypical Guadeloupean parkinsonism comprises two forms of parkinsonism and dementia that differ clinically by the presence of oculomotor signs, but have similar cognitive profiles and neuroimaging features, suggesting that they may constitute a single disease entity, and both were similarly exposed to annonaceous neurotoxins, notably annonacin.
在瓜德罗普岛,非典型帕金森症的发病率异常高。据报道,出现帕金森症状的患者中,只有三分之一表现出特发性帕金森病的典型特征,三分之一表现出类似进行性核上性麻痹(PSP)的综合征。根据既定标准,其他患者无法分类。我们对160名帕金森病患者进行了一项横断面研究,目的是:(i)更精确地定义PSP样综合征和与先前已知疾病相比被认为无法分类的帕金森症的临床表型;(ii)确定这些患者的神经心理学和脑成像特征;(iii)评估一种候选病因因素——热带植物刺果番荔枝(刺番荔枝)的果实和叶子中含有的线粒体复合体I抑制剂annonacin在这种神经综合征中所起的作用程度。通过神经心理学测试和核磁共振成像(MRI)将患者分为帕金森病患者(31%)、瓜德罗普岛PSP样综合征患者(32%)、瓜德罗普岛帕金森痴呆综合征(PDC,31%)和其他帕金森相关疾病患者(6%)。PSP样综合征患者出现左旋多巴抵抗性帕金森症,伴有早期姿势不稳和核上性动眼功能障碍。然而,他们与典型PSP患者的不同之处在于震颤频率(>50%)、自主神经功能障碍(50%)和幻觉发生率(59%)。PDC患者有左旋多巴抵抗性帕金森症,伴有额颞叶皮质下痴呆,这些患者中有52%出现幻觉,但重要的是,没有患者有动眼功能障碍。两个亚组的神经心理学缺陷模式相似。大多数PSP样和PDC患者出现脑萎缩,第三脑室扩大,基底节尤其是黑质有明显的T2低信号。PSP样和PDC患者的刺番荔枝摄入量均显著高于对照组和帕金森病患者。总之,非典型瓜德罗普岛帕金森症包括两种帕金森症和痴呆形式,它们在临床上因动眼体征的存在而有所不同,但具有相似的认知特征和神经成像特征,这表明它们可能构成一个单一的疾病实体,并且两者都同样暴露于番荔枝神经毒素,尤其是annonacin。